Page last updated: 2024-10-27

gentamicin and Carcinoma, Epidermoid

gentamicin has been researched along with Carcinoma, Epidermoid in 12 studies

Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.

Research Excerpts

ExcerptRelevanceReference
"Corynebacterium diphtheriae, generally considered an extracellular coloniser, was evaluated for its ability to enter and survive within HEp-2 monolayers by gentamicin protection assay."3.71Intracellular viability of toxigenic Corynebacterium diphtheriae strains in HEp-2 cells. ( Andrade, AF; Fonseca, LS; Formiga, LC; Hirata, R; Mattos-Guaraldi, AL; Monteiro-Leal, LH; Nagao, PE; Napoleão, F, 2002)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (33.33)18.2507
2000's5 (41.67)29.6817
2010's3 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Martínez-Doménech, Á1
García-Legaz Martínez, M1
Magdaleno-Tapial, J1
Valenzuela-Oñate, C1
Pérez-Pastor, G1
Pérez-Ferriols, A1
Yang, CH1
Chew, KY1
Solomkin, JS1
Lin, PY1
Chiang, YC1
Kuo, YR1
Thatcher, N1
Hirsch, FR1
Luft, AV1
Szczesna, A1
Ciuleanu, TE1
Dediu, M1
Ramlau, R1
Galiulin, RK1
Bálint, B1
Losonczy, G1
Kazarnowicz, A1
Park, K1
Schumann, C1
Reck, M1
Depenbrock, H1
Nanda, S1
Kruljac-Letunic, A1
Kurek, R1
Paz-Ares, L1
Socinski, MA1
Hirata, R1
Napoleão, F1
Monteiro-Leal, LH1
Andrade, AF1
Nagao, PE1
Formiga, LC1
Fonseca, LS1
Mattos-Guaraldi, AL1
Duncan, GG1
Epstein, JB1
Tu, D1
El Sayed, S1
Bezjak, A1
Ottaway, J1
Pater, J1
Campbell, RM1
Perlis, CS1
Fisher, E1
Gloster, HM1
Inagaki, T2
Matsuwari, S2
Shimada, K2
Abe, N1
Takahashi, R2
Maeda, S2
Fujie, K1
Berardi, RS1
Ena, P1
Lissia, M1
Doneddu, GM1
Campus, GV1
Ji, ZW1
Oku, N1
Komori, T1
El-Sayed, S1
Epstein, J1
Minish, E1
Burns, P1
Hay, J1
Laukkanen, E1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients Who Receiving Radical Concurrent Chemoradiotherapy and Immunotherapy: a Prospective, Randomized Controlled, Multicenter P[NCT04980716]Phase 3524 participants (Anticipated)Interventional2021-06-01Recruiting
An Open-label, Randomized Phase III Study of Early Switch Maintenance vs DElayed Second-line Nivolumab in Advanced Stage Squamous Non Small-cell Lung Cancer (NSCLC) Patients After Standard First-line Platinum-based Chemotherapy - EDEN Trial[NCT03542461]Phase 3125 participants (Actual)Interventional2017-09-25Active, not recruiting
A Randomized, Multicenter, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer[NCT00981058]Phase 31,093 participants (Actual)Interventional2010-01-07Active, not recruiting
Randomized Evaluation of a Phytopharmaceutical in Prevention of Severe Oral Mucositis in Patients Receiving Radiotherapy for Oral Cavity, Oropharynx, Hypopharynx, or Cavum Cancer[NCT01066741]Phase 378 participants (Actual)Interventional2009-05-31Terminated (stopped due to insufficient recruitment, the planed sample size appears not achievable)
The Effectiveness of Topical Oral Vitamin D Gel in Prevention of Radiation-induced Oral Mucositis[NCT04308161]Phase 245 participants (Anticipated)Interventional2019-11-02Recruiting
The Effectiveness of Melatonin in Prevention of Radiation-induced Oral Mucositis[NCT03833570]Phase 240 participants (Actual)Interventional2018-01-12Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Mean Change From Baseline in Patient Reported Outcomes (PRO) Using the European Quality of Life-5 Dimension (EQ-5D)

The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a three level scale 1-3 (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). (NCT00981058)
Timeframe: Baseline, Cycle 6 (Cycle = 3 Weeks)

Interventionunits on a scale (Mean)
Necitumumab + Gemcitabine + Cisplatin-0.0053
Gemcitabine + Cisplatin-0.0083

Overall Survival Time (OS)

Overall survival is defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive. OS was estimated by the Kaplan-Meier method. (NCT00981058)
Timeframe: Randomization to Death from Any Cause (Up to 31 Months)

InterventionMonths (Median)
Necitumumab + Gemcitabine + Cisplatin11.5
Gemcitabine + Cisplatin9.9

Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) (Objective Response Rate [ORR])

ORR is confirmed best overall tumor response of CR or PR. According to RECIST v1.0, CR was defined as the disappearance of all target and non-target lesions. PR defined as a >=30% decrease in the sum of the longest diameters (LD) of the target lesions, taking as reference the baseline sum of the LD; Percentage of participants was calculated as: (total number of participants with CR or PR from start of the treatment until disease progression or recurrence)/total number of participants treated) * 100. (NCT00981058)
Timeframe: Baseline to Measured Progressive Disease (Up to 31 Months)

Interventionpercentage of participants (Number)
Necitumumab + Gemcitabine + Cisplatin31.2
Gemcitabine + Cisplatin28.8

Progression-Free Survival (PFS)

PFS is defined as the time from randomization until the first radiographic documentation of objective measured progressive disease as defined by RECIST (Version 1.0), or death from any cause. Progressive Disease (PD) was defined as having at least a 20% increase in the sum of the longest diameter of target lesions. Participants who die without a reported prior progression were considered to have progressed on the day of their death. Participants who did not progress or were lost to follow-up were censored at the day of their last radiographic tumor assessment. If no baseline or postbaseline radiologic assessment was available, the participants were censored at the date of randomization. If death or PD occurs after two or more consecutive missing radiographic visits, censoring occurred at the date of the last radiographic visit prior to the missed visits. (NCT00981058)
Timeframe: Randomization to Measured Progressive Disease or Death from Any Cause (Up to 31 Months)

Interventionmonths (Median)
Necitumumab + Gemcitabine + Cisplatin5.7
Gemcitabine + Cisplatin5.5

Time to Treatment Failure (TTF)

TTF is defined as the time from the date of randomization until the date of the first radiographic documentation of PD, death from any cause, discontinuation of treatment for any reason, or initiation of new cancer therapy. Participants who withdrew from the study for reasons other than progression or death were censored at the date of study withdrawal. Participants who did not meet any of the criteria for treatment failure were censored at their date of last contact in the study. (NCT00981058)
Timeframe: Randomization to Measured Progressive Disease, Death From Any Cause, Discontinuation of Treatment or Initiation of New Anticancer Therapy (Up to 31 Months)

InterventionMonths (Median)
Necitumumab + Gemcitabine + Cisplatin4.3
Gemcitabine + Cisplatin3.6

Mean Change From Baseline in PRO Using the Outcomes Lung Cancer Symptom Scale (LCSS)

The LCSS consisted of 9 items: 6 items focused on lung cancer symptoms [loss of appetite, fatigue, cough, dyspnea (shortness of breath), hemoptysis (blood in sputum), and pain] and 3 items were global items (symptom distress, interference with activity level, and global quality of life). Participant responses to each item were measured using visual analogue scales (VAS) with 100-mm lines. A higher score for any item represented a higher level of symptoms/problems. Scores for each of the reported categories ranged from 0 (for best outcome) to 100 (for worst outcome). The Average Symptom Burden Index (ASBI) was the mean of the 6 symptom items of the LCSS, and the Total LCSS was the mean of all 9 LCSS items. ASBI and Total LCSS were not computed for a participant if he/she had 1 or more missing values for the 6 and 9 items, respectively. (NCT00981058)
Timeframe: Baseline, Cycle 6 (Cycle = 3 Weeks)

,
Interventionmillimeter (mm) (Mean)
Loss of Appetite (n=304, 242)Fatigue (n=302, 242)Cough (n=303, 243)Dyspnea (n=305, 244)Pain (n=302, 243)Overall Symptoms (n=303, 242)Interference (n=306,241)Quality of Life (n=305, 243)Average Symptom Burden Index (ASBI) (n=294, 234)LCSS Total Score (n=290, 228)
Gemcitabine + Cisplatin1.53.5-9.1-1.8-2.2-0.62.2-1.6-1.5-0.8
Necitumumab + Gemcitabine + Cisplatin1.86.3-7.8-2.8-3.3-0.33.8-0.3-1.9-0.8

Number of Participants With a Serum Anti-Necitumumab Antibody Assessment

A participant was considered to have an anti-Necitumumab antibody response if anti-drug antibodies (ADA) were detected at any time point. (NCT00981058)
Timeframe: Baseline through 31 Months

Interventionparticipants (Number)
Participants with at least 1 positive titerNeutralizing antibody detected
Necitumumab + Gemcitabine + Cisplatin815

Number of Participants With an Epidermal Growth Factor Hormone (EGFR) Protein Expression Measured by Immunohistochemistry (IHC)

EGFR IHC Histoscore H-score = weighted sum of % 1+ cells, twice % 2+ cells, and three times % 3+ cells. IHC H-score criteria was used to assess participants with a low EGFR expression defined by a H-score cutoff value of <200 and participants with a high EGFR expression defined by a H-score of cutoff value of >=200. (NCT00981058)
Timeframe: 31 Months

,
Interventionparticipants (Number)
0>0<200≥200
Gemcitabine + Cisplatin23473313183
Necitumumab + Gemcitabine + Cisplatin24462295191

Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab

(NCT00981058)
Timeframe: Day 1 of Cycle 2, 3, 4, 5 and 6 Prior to Necitumumab Drug Infusion, Up to 24 Months

Interventionmicrograms/milliliter (ug/mL) (Geometric Mean)
Predose Cycle 2 Day 1 (n=419)Predose Cycle3 Day 1 (n=386)Predose Cycle 4 Day 1 (n=344)Predose Cycle 5 Day 1 (n=297)Predose Cycle 6 Day 1 (n=262)
Necitumumab + Gemcitabine + Cisplatin52.476.694.510198.5

Reviews

1 review available for gentamicin and Carcinoma, Epidermoid

ArticleYear
Erosive pustular dermatosis of the scalp in skin grafts: report of three cases.
    Dermatology (Basel, Switzerland), 1997, Volume: 194, Issue:1

    Topics: Administration, Cutaneous; Administration, Oral; Aged; Anti-Bacterial Agents; Anti-Infective Agents;

1997

Trials

3 trials available for gentamicin and Carcinoma, Epidermoid

ArticleYear
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:7

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz

2015
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:7

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz

2015
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:7

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz

2015
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:7

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz

2015
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:7

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz

2015
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:7

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz

2015
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:7

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz

2015
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:7

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz

2015
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:7

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz

2015
Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis.
    Head & neck, 2005, Volume: 27, Issue:5

    Topics: Administration, Oral; Anti-Infective Agents; Bacitracin; Carcinoma, Squamous Cell; Clotrimazole; Dou

2005
Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis.
    Head & neck, 2005, Volume: 27, Issue:5

    Topics: Administration, Oral; Anti-Infective Agents; Bacitracin; Carcinoma, Squamous Cell; Clotrimazole; Dou

2005
Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis.
    Head & neck, 2005, Volume: 27, Issue:5

    Topics: Administration, Oral; Anti-Infective Agents; Bacitracin; Carcinoma, Squamous Cell; Clotrimazole; Dou

2005
Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis.
    Head & neck, 2005, Volume: 27, Issue:5

    Topics: Administration, Oral; Anti-Infective Agents; Bacitracin; Carcinoma, Squamous Cell; Clotrimazole; Dou

2005
Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis.
    Head & neck, 2005, Volume: 27, Issue:5

    Topics: Administration, Oral; Anti-Infective Agents; Bacitracin; Carcinoma, Squamous Cell; Clotrimazole; Dou

2005
Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis.
    Head & neck, 2005, Volume: 27, Issue:5

    Topics: Administration, Oral; Anti-Infective Agents; Bacitracin; Carcinoma, Squamous Cell; Clotrimazole; Dou

2005
Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis.
    Head & neck, 2005, Volume: 27, Issue:5

    Topics: Administration, Oral; Anti-Infective Agents; Bacitracin; Carcinoma, Squamous Cell; Clotrimazole; Dou

2005
Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis.
    Head & neck, 2005, Volume: 27, Issue:5

    Topics: Administration, Oral; Anti-Infective Agents; Bacitracin; Carcinoma, Squamous Cell; Clotrimazole; Dou

2005
Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis.
    Head & neck, 2005, Volume: 27, Issue:5

    Topics: Administration, Oral; Anti-Infective Agents; Bacitracin; Carcinoma, Squamous Cell; Clotrimazole; Dou

2005
A pilot study evaluating the safety and microbiologic efficacy of an economically viable antimicrobial lozenge in patients with head and neck cancer receiving radiation therapy.
    Head & neck, 2002, Volume: 24, Issue:1

    Topics: Administration, Oral; Adult; Aged; Bacitracin; Carcinoma, Squamous Cell; Clotrimazole; Female; Follo

2002

Other Studies

8 other studies available for gentamicin and Carcinoma, Epidermoid

ArticleYear
Digital ulcerative lichenoid dermatitis in a patient receiving anti-PD-1 therapy.
    Dermatology online journal, 2019, Sep-15, Volume: 25, Issue:9

    Topics: Administration, Cutaneous; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunolog

2019
Surgical site infections among high-risk patients in clean-contaminated head and neck reconstructive surgery: concordance with preoperative oral flora.
    Annals of plastic surgery, 2013, Volume: 71 Suppl 1

    Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Carcinoma, Squamous Cell; Clindamycin; F

2013
Intracellular viability of toxigenic Corynebacterium diphtheriae strains in HEp-2 cells.
    FEMS microbiology letters, 2002, Sep-24, Volume: 215, Issue:1

    Topics: Anti-Bacterial Agents; Carcinoma, Squamous Cell; Corynebacterium diphtheriae; Diphtheria; Endocardit

2002
Gentamicin ointment versus petrolatum for management of auricular wounds.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2005, Volume: 31, Issue:6

    Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Carcinoma, Basal Cell; Carcinoma, Squamous Cel

2005
[Effective removal of the contaminating host fibroblasts for establishment of human-tumor cultured lines].
    Human cell, 1993, Volume: 6, Issue:2

    Topics: Aged; Animals; Carcinoma, Squamous Cell; Cell Division; Cell Separation; Culture Media; Female; Fibr

1993
Establishment of human oral-cancer cell lines (KOSC-2 and -3) carrying p53 and c-myc abnormalities by geneticin treatment.
    International journal of cancer, 1994, Jan-15, Volume: 56, Issue:2

    Topics: Aged; Animals; Carcinoma, Squamous Cell; Cell Division; Chromosome Aberrations; DNA, Neoplasm; Femal

1994
Morbidity after abdomino-perineal resection.
    American journal of surgery, 1993, Volume: 166, Issue:3

    Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Gentamicins; Humans; Perineum; Surgical Wound Infection; W

1993
Establishment of a novel human squamous cell carcinoma cell line from oral primary tumor by geneticin treatment.
    The Kobe journal of medical sciences, 2000, Volume: 46, Issue:3

    Topics: Animals; Carcinoma, Squamous Cell; Cytological Techniques; Gentamicins; Gingival Neoplasms; Humans;

2000